(It’s useful to clearly distinguish exploration of what follows from some premises, and views on whether the premises are important/likely/feasible. Issues with the latter are no reason at all to hesitate or hedge with the former.)
But that means you again assume that arbitrary nanotech is feasible, which could be true, but as the other link notes, certainly isn’t anything like obvious.
I mentioned arbitrary nanotech, but it’s not doing any work there as an assumption. So it being infeasible doesn’t change the point about macroscopic biotech possibly being first, which is technically still the case if nanotech doesn’t follow at all.
Various claims that nanotech isn’t feasible are indeed the major reason I thought about this macroscopic biotech thing, since existing biology is a proof of concept, so some of the arguments against feasibility of nanotech clearly don’t transfer. It still needs to be designed, and the difficulty of that is unclear, but there seem to be fewer reasons to suspect it’s not feasible (at a given level of capabilities).
The macroscopic biotech that accomplishes what you’re positing is addressed in the first part, and the earlier comment where I note that you’re assuming ASI level understanding of bio for exploring an exponential design space for something that isn’t guaranteed to be possible. The difficulty isn’t unclear, it’s understood not to bebfeasible.
(It’s useful to clearly distinguish exploration of what follows from some premises, and views on whether the premises are important/likely/feasible. Issues with the latter are no reason at all to hesitate or hedge with the former.)
I mentioned arbitrary nanotech, but it’s not doing any work there as an assumption. So it being infeasible doesn’t change the point about macroscopic biotech possibly being first, which is technically still the case if nanotech doesn’t follow at all.
Various claims that nanotech isn’t feasible are indeed the major reason I thought about this macroscopic biotech thing, since existing biology is a proof of concept, so some of the arguments against feasibility of nanotech clearly don’t transfer. It still needs to be designed, and the difficulty of that is unclear, but there seem to be fewer reasons to suspect it’s not feasible (at a given level of capabilities).
The macroscopic biotech that accomplishes what you’re positing is addressed in the first part, and the earlier comment where I note that you’re assuming ASI level understanding of bio for exploring an exponential design space for something that isn’t guaranteed to be possible. The difficulty isn’t unclear, it’s understood not to bebfeasible.